View Item 

Show simple item record

Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment
dc.contributor.authorLok, A. S.
dc.contributor.authorGanova‐raeva, L.
dc.contributor.authorCloonan, Y.
dc.contributor.authorPunkova, L.
dc.contributor.authorLin, H.‐h. S.
dc.contributor.authorLee, W. M.
dc.contributor.authorGhany, M. G.
dc.date.accessioned2017-10-23T17:31:47Z
dc.date.available2019-01-07T18:34:38Zen
dc.date.issued2017-11
dc.identifier.citationLok, A. S.; Ganova‐raeva, L. ; Cloonan, Y.; Punkova, L.; Lin, H.‐h. S. ; Lee, W. M.; Ghany, M. G. (2017). "Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment." Journal of Viral Hepatitis 24(11): 1032-1042.
dc.identifier.issn1352-0504
dc.identifier.issn1365-2893
dc.identifier.urihttps://hdl.handle.net/2027.42/138913
dc.publisherWiley Periodicals, Inc.
dc.subject.otherhepatitis B virus
dc.subject.otherantiviral treatment
dc.subject.othernext generation sequencing
dc.subject.othernucleos(t)ide analogues
dc.subject.otherSanger sequencing
dc.titlePrevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/138913/1/jvh12732.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/138913/2/jvh12732_am.pdf
dc.identifier.doi10.1111/jvh.12732
dc.identifier.sourceJournal of Viral Hepatitis
dc.identifier.citedreferenceMargeridonâ Thermet S, Shulman NS, Ahmed A, Shahriar R, Liu T, Wang C, et al. Ultraâ deep pyrosequencing of Hepatitis B virus quasispecies from nucleoside and nucleotide reverseâ transcriptase inhibitor (NRTI)â treated patients and NRTIâ naive patients. J Infect Dis. 2009; 199: 1275 â 1285.
dc.identifier.citedreferenceSchweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic Hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015; 386: 1546 â 1555.
dc.identifier.citedreferenceZoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009; 137: 1593 â 1608. e1â 2.
dc.identifier.citedreferenceLok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, et al. Antiviral drugâ resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology. 2007; 46: 254 â 265.
dc.identifier.citedreferenceOno SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, et al. The polymerase L528M mutation cooperates with nucleotide bindingâ site mutations, increasing Hepatitis B virus replication and drug resistance. J Clin Invest. 2001; 107: 449 â 455.
dc.identifier.citedreferenceTeo CG, Locarnini SA. Potential threat of drugâ resistant and vaccineâ escape HBV mutants to public health. Antivir Ther. 2010; 15 ( 3 Pt B ): 445 â 449.
dc.identifier.citedreferenceZhang Q, Liao Y, Cai B, Li Y, Li L, Zhang J, et al. Incidence of natural resistance mutations in naive chronic hepatitis B patients: a systematic review and metaâ analysis. J Gastroenterol Hepatol. 2015; 30: 252 â 261.
dc.identifier.citedreferenceLowe CF, Merrick L, Harrigan PR, Mazzulli T, Sherlock CH, Ritchie G. Implementation of nextâ generation sequencing for Hepatitis B virus resistance testing and genotyping in a clinical microbiology laboratory. J Clin Microbiol. 2016; 54: 127 â 133.
dc.identifier.citedreferenceGhany MG, Perrillo R, Li R, Belle SH, Janssen HL, Terrault NA, et al. Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and Hepatitis B virus genotype. Clin Gastroenterol Hepatol. 2015; 13: 183 â 192.
dc.identifier.citedreferenceGanovaâ Raeva L, Ramachandran S, Honisch C, Forbi JC, Zhai X, Khudyakov Y. Robust Hepatitis B virus genotyping by mass spectrometry. J Clin Microbiol. 2010; 48: 4161 â 4168.
dc.identifier.citedreferenceNguyen MH, Garcia RT, Trinh HN, Nguyen HA, Nguyen KK, Nguyen LH, et al. Prevalence of Hepatitis B virus DNA polymerase mutations in treatmentâ naive patients with chronic hepatitis B. Aliment Pharmacol Ther. 2009; 30: 1150 â 1158.
dc.identifier.citedreferenceVutien P, Trinh HN, Garcia RT, Nguyen HA, Levitt BS, Nguyen K, et al. Mutations in HBV DNA polymerase associated with nucleos(t)ide resistance are rare in treatmentâ naive patients. Clin Gastroenterol Hepatol. 2014; 12: 1363 â 1370.
dc.identifier.citedreferenceMargeridonâ Thermet S, Svarovskaia ES, Babrzadeh F, Martin R, Liu TF, Pacold M, et al. Lowâ level persistence of drug resistance mutations in Hepatitis B virusâ infected subjects with a past history of Lamivudine treatment. Antimicrob Agents Chemother. 2013; 57: 343 â 349.
dc.identifier.citedreferenceSvarovskaia ES, Curtis M, Zhu Y, Borrotoâ Esoda K, Miller MD, Berg T, et al. Hepatitis B virus wildâ type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovirâ based regimen. J Viral Hepat. 2013; 20: 131 â 140.
dc.identifier.citedreferenceLiu Y, Fung S, Gane EJ, Dinh P, Flaherty JF, Svarovskaia ES, et al. Evaluation of HBV DNA decay kinetics in patients containing both rtM204V/I mutant and wildâ type HBV subpopulations during tenofovir DF (TDF) monotherapy or combination therapy with emtricitabine (FTC)/TDF. J Med Virol. 2014; 86: 1473 â 1481.
dc.identifier.citedreferenceSolmone M, Giombini E, Vincenti D, Rozera G, Testa A, Moscetti A, et al. Slow response to entecavir treatment in treatmentâ naive HBV patients is conditioned by immune response rather than by the presence or selection of refractory variants. Antivir Ther. 2014; 19: 201 â 209.
dc.identifier.citedreferenceWHO. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. 2015. http://www.who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/. Accessed June 17, 2017.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jvh12732.pdf
Size:
431.7KB
Format:
PDF
View/Open
Name:
jvh12732_am.pdf
Size:
378.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.